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Purpose of the study
Among the currently available antiretroviral drugs, the
novel integrase inhibitor raltegravir (RAL) is an oral agent
without cross-resistance to any other antiretroviral family
and it provides an option with easier administration and
better tolerability than enfuvirtide (ENF). There is no
experience in routine clinical practice with RAL as a sim-
plification strategy. We evaluate the efficacy and safety of
switching ENF to RAL as a simplification strategy for a fol-
low-up of 24 and 48 weeks in patients with an HIV-1 viral
load (VL) < 50 copies/mL.
Methods
In this retrospective cohort, patients from routine clinical
practice on a suppressive ENF-containing regimen were
selected. The patients were switched from ENF to RAL
while the rest of the antiretroviral regimen remained
unchanged. According to standard clinical practice, we
assessed the VL, CD4+ T-cell count, hepatic enzymes and
fasted lipid profile. Results after a 24-week period of fol-
low-up are shown in this analysis. Sixteen patients were
included in this analysis. At baseline, the median number
of prior antiretrovirals was 12 (9–16). The means of time
on ENF treatment and time with viral suppression were
126 (SD: 62) and 98 (SD: 57) weeks, respectively. The
concurrent treatments included DRV/r in 10 (62.5%)
patients, TPV/r in five (31.2%) and ETV in two (12.5%)
more subjects. The 100% of patients achieved 24 weeks
with sustained viral suppression. Median CD4+ T-cell
count increased from 374 (272–466) cells/mL at baseline
to 408 (308–541) cells/mL at week 24 of follow-up (p =
0.087). There were no significant changes in total choles-
terol, HDL cholesterol, LDL cholesterol and triglycerides
(p = 0.103, p = 0.934, p = 0.978 and p = 0.696, retrospec-
tively). Similarly, there were no significant changes in
AST, ALT and ALP (p = 0.156, p = 0.475 and p = 0.487,
respectively). Only the gamma-GT improved significantly,
showing a reduction from 58.5 (32.2–78.7) U/L at base-
line to 37 (22.5–54) U/L at week 24 of follow-up (p =
0.023). Injection site reactions were solved in all patients
after switching and there were no significant adverse
events related with RAL administration.
Conclusion
Switching ENF to RAL seems to be safe and effective in the
short-term in patients with viral suppression despite a
prior high antiretroviral experience. Its long-term impact
on patient's adherence, quality of life, safety and efficacy
should be evaluated in clinical trials.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P58 doi:10.1186/1758-2652-11-S1-P58
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P58
© 2008 Santos et al; licensee BioMed Central Ltd. 
